Radicle Spark for Women™ 24: Assessing the Impact of Health and Wellness Products on Sexual Health and Related Health Outcomes

Launched by RADICLE SCIENCE · Mar 17, 2025

Keywords

ClinConnect Summary

The Radicle Spark for Women™ 24 trial is studying how certain health and wellness products can affect sexual health, specifically focusing on sexual satisfaction and function. The goal is to see if these products can help improve libido (sex drive) and overall sexual experiences for women. This study is currently looking for women aged 21 and older who live in the United States and are interested in enhancing their sexual health.

To participate, you should be willing to try a product without knowing if you are receiving the actual product or a placebo (which looks like the real thing but has no active ingredients). However, there are some important criteria for eligibility. For example, you should not be pregnant or breastfeeding, and you should not have certain health conditions that could make participation unsafe. If you join the trial, you can expect to use the study product for a specific period and share your experiences, which will help researchers understand its effects on sexual health.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities - Assigned sex at birth is female
• • Resides in the United States
• • Endorses improved libido (sex drive), sexual satisfaction and/or function as a primary desire
• • Has the opportunity for at least 30% improvement in their primary health outcome
• • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
• Exclusion Criteria:
• • Report being pregnant, trying to become pregnant, or breastfeeding
• • Unable to provide a valid US shipping address and mobile phone number
• • Reports current enrollment in another clinical trial
• • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
• • Unable to read and understand English
• • Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
• • Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.
• • o NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
• • Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.
• • o Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products
• • Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products
• • Lack of reliable daily access to the internet